ADPKD Patient Registry

Polycystic Kidney Diseases Clinical Trial

— ADPKD  

Official title:

Autosomal Dominant Polycystic Kidney Disease Patient Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04039061
• Other study ID #: 120190065
• Status: Recruiting
• Start date: September 4, 2019
• Est. completion date: September 4, 2029

Study information

• Verified date: November 2023
• Source: PKD Foundation
• Contact: Elise Hoover
• Phone: 816-268-8478
• Email: eliseh[@]pkdcure.org
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of the ADPKD Registry is to create an online patient network that includes at least 5,000 people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who contribute data on their health and other topics. The ADPKD Patient Registry aims to support important scientific discoveries and support patient needs in the following ways:

• Connect ADPKD patients with opportunities to join clinical studies.

• Collect data for the research community to better describe the ADPKD disease experience and improve patient care.

• Engage with patients by measuring quality of life outcomes.

Description:

The ADPKD Registry will be a patient-powered network of people with ADPKD. This data will inform new research to improve ADPKD patient outcomes, learn more about the patient journey and discover unmet medical needs. We collect data most relevant to your ADPKD diagnosis, its major symptoms and management, as well as key demographic data (no personally identifiable information is shared). A Registry keeps information in one place making it easier for researchers to utilize Registry information while still protecting the privacy of those who take part. The Registry will be hosted on a secure, online platform that patients can access using their home computers, tablets or phones.

The purpose of the ADPKD Registry is to allow PKD patients to:

• Connect with researchers and express interest in taking part in certain clinical studies for ADPKD, including studies of new medications and other treatments.

• Take confidential health-related surveys. These surveys are aimed at better understanding of the health of people with PKD across their lifespans.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: September 4, 2029
• Est. primary completion date: September 4, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Diagnosis or suspected diagnosis with autosomal dominant polycystic kidney disease (ADPKD)

Exclusion Criteria:

• caretakers, family members or friends of individuals with ADPKD

Related Conditions & MeSH terms

• Kidney Diseases
• Polycystic Kidney Diseases

Locations

Country	Name	City	State
United States	PKD Foundation	Kansas City	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
PKD Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of people with polycystic kidney disease who experience health-related quality-of-life changes	To be assessed with online modules, developed both internally and through validated partners	1 year

External Links

•   ADPKD Patient Registry webpage